Results 91 to 100 of about 49,863 (128)

NRas Nanoclusters Mediate Crosstalk Between BRAF/ERK and PI3K/AKT Signaling in Melanoma Cells. [PDF]

Int J Mol Sci
Yakovian O, Sajman J, Sherman E.
europepmc   +1 more source

Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. [PDF]

Transl Oncol
Gazzah A, Ternès N, Lee JS, Wang E, Carene D, Wang H, Masson N, Boitier E, Lartigau A, Mace N, Chadjaa M, Dib C, Nunes M, Muzard G, Longuemaux-Valence S, Bauchet AL.   +15 more
europepmc   +1 more source

Enhanced Killing of Colon Cancer Cells by Mesoporous Silica Nanoparticles Loaded with Ellagic Acid. [PDF]

Nanomaterials (Basel)
AbouAitah K, Nassrallah A, Soliman AAF, Swiderska-Sroda A, Chudoba T, Smalc-Koziorowska J, Kim BS, Łojkowski W.   +7 more
europepmc   +1 more source

TRAF7 in signaling and disease: emerging mechanisms and clinical implications. [PDF]

Mol Med
Orock A, Zuccato JA, Phan K, Liu Y, Ihuoma J, Tavakol S, Tsytsykova AV, Tsitsikov EN, Tarantini S, Johnson AC, Dunn IF.   +10 more
europepmc   +1 more source

In-silico pharmacological insights into the therapeutic potential of microRNAs for microplastic-associated cancers. [PDF]

Front Cell Dev Biol
Baspakova A, Zare A, Mussin NM, Tanideh N, Zhilisbayeva KR, Safarzoda Sharoffidin R, Suleimenova R, Yelgondina G, Kaliyeva AE, Umbetova AA, Zinaliyeva A, Tamadon A.   +11 more
europepmc   +1 more source

Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular basis and new targets. [PDF]

Front Oncol
Peng H, Li M, Peng YY, Li XL, Yang J, Sun QG, Song K.   +6 more
europepmc   +1 more source

Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer. [PDF]

Acta Oncol
Bar J, Cai MH, Choi YC, Baijal S, Zhao W, Liede A, Vasilopoulos A, Roberts-Rapp L, Jiang F, Simmons A, Ratajczak C, Lu S, Ansell PJ, Camidge DR.   +13 more
europepmc   +1 more source

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports. [PDF]

Oncologist
He X, Xie S, Jia C, Wu X, Chen Z, Wang T.   +5 more
europepmc   +1 more source

Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells. [PDF]

Cancer Chemother Pharmacol
Zhu H, Yan G, Ma J, Zhang B, Yan Y, Zhu L, Dong R, Lin N, Tan B.   +8 more
europepmc   +1 more source

Prognostic and predictive value of AXL and C-MET in patients with rectal cancer. [PDF]

Arq Bras Cir Dig
Ribas CAPM, N Doelken E, Tripathi S, Polat B, Lissner R, Böeldicke T, Ribas-Filho JM, Malafaia O, Gasser M, Waaga-Gasser AM.   +9 more
europepmc   +1 more source